Researchers at BC Cancer are hoping to speak with advanced ovarian (high-grade serous, BRCA-negative) cancer patients about their experiences with HRD testing and PARP inhibitors. The findings from the study will be used to better understand patient experiences to inform future policy and research. The study is a one time, one-to-one interview that will take approximately 60 minutes, be held through telephone or virtually through Teams, and you will be provided with an honorarium for your time. If you are interested in participating, please follow the survey link at https://tinyurl.com/HRDStudy or contact Julia McKenna (jmckenna@bccrc.ca) from the research team for more information.
-------------------------------------------